ES2530392T3 - Uso del nintedanib para el tratamiento de la fibrosis pulmonar - Google Patents
Uso del nintedanib para el tratamiento de la fibrosis pulmonar Download PDFInfo
- Publication number
- ES2530392T3 ES2530392T3 ES03792292T ES03792292T ES2530392T3 ES 2530392 T3 ES2530392 T3 ES 2530392T3 ES 03792292 T ES03792292 T ES 03792292T ES 03792292 T ES03792292 T ES 03792292T ES 2530392 T3 ES2530392 T3 ES 2530392T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- pulmonary fibrosis
- nintedanib
- methyl
- indolinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000005069 pulmonary fibrosis Diseases 0.000 title abstract 2
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 title 1
- 229960004378 nintedanib Drugs 0.000 title 1
- -1 4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -phenylamino Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10237423A DE10237423A1 (de) | 2002-08-16 | 2002-08-16 | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| PCT/EP2003/008890 WO2004017948A2 (en) | 2002-08-16 | 2003-08-11 | Use of lck inhibitor for treatment of immunologic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2530392T3 true ES2530392T3 (es) | 2015-03-02 |
Family
ID=30469754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03792292T Expired - Lifetime ES2530392T3 (es) | 2002-08-16 | 2003-08-11 | Uso del nintedanib para el tratamiento de la fibrosis pulmonar |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP2281561A3 (https=) |
| JP (1) | JP2006514611A (https=) |
| AU (1) | AU2003255413A1 (https=) |
| CA (1) | CA2495350C (https=) |
| CY (1) | CY1116093T1 (https=) |
| DE (1) | DE10237423A1 (https=) |
| DK (1) | DK1530466T3 (https=) |
| ES (1) | ES2530392T3 (https=) |
| PT (1) | PT1530466E (https=) |
| SI (1) | SI1530466T1 (https=) |
| WO (1) | WO2004017948A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20060154939A1 (en) * | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| WO2007057399A2 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| WO2007057397A1 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
| FR2909876A1 (fr) * | 2006-12-19 | 2008-06-20 | Galderma Res & Dev S N C Snc | Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques |
| WO2008098734A1 (en) | 2007-02-12 | 2008-08-21 | Stefan Hansson | Diagnosis and treatment of preeclampsia |
| PT2293795E (pt) | 2008-06-06 | 2015-11-17 | Boehringer Ingelheim Int | Combinação farmacêutica |
| HRP20160760T1 (hr) * | 2008-07-18 | 2016-08-12 | A1M Pharma Ab | Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina |
| US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| US20120142703A1 (en) | 2009-05-14 | 2012-06-07 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| JP6799201B2 (ja) * | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク． | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
| EP2837626A1 (en) * | 2013-08-16 | 2015-02-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Indolinone derivatives as GRK5 modulators |
| US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| US20190160054A1 (en) | 2016-04-13 | 2019-05-30 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer |
| EP3246029A1 (en) | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
| US20190275032A1 (en) | 2016-05-27 | 2019-09-12 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone |
| WO2017207643A1 (en) | 2016-06-01 | 2017-12-07 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
| EP3600322A1 (en) | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib for use in methods for the treatment of muscular dystrophy |
| CN112004527B (zh) | 2018-04-23 | 2024-09-24 | 盈擘生技股份有限公司 | 用于治疗肺部疾病的可吸入脂质体缓释组合物 |
| CN111285872B (zh) * | 2018-12-06 | 2022-05-17 | 北京志健金瑞生物医药科技有限公司 | 吲哚-2-酮衍生物及其制备方法与用途 |
| WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| JP2025525881A (ja) | 2022-08-16 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼内使用するためのニンテダニブの医薬製剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0892248A (ja) * | 1994-09-26 | 1996-04-09 | Yamanouchi Pharmaceut Co Ltd | インドリノン誘導体 |
| GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| WO1998024432A2 (en) * | 1996-12-05 | 1998-06-11 | Sugen, Inc. | Use of indolinone compounds as modulators of protein kinases |
| DE69828607T2 (de) * | 1997-05-28 | 2006-01-05 | Aventis Pharmaceuticals Inc. | CHINOLIN- UND CHINOXALIN-VERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMMENDEN WACHSTUMSFAKTOR UND/ODER PDGF- UND P56lck-TYROSIN-KINASE HEMMEN |
| DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| PT1115704E (pt) | 1998-09-25 | 2003-11-28 | Boehringer Ingelheim Pharma | Novas indolinonas substituidas com accao inibidora sobre varias quinases e complexos ciclina/cdk |
| DE19924401A1 (de) | 1999-05-27 | 2000-11-30 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1222187B1 (en) * | 1999-10-06 | 2004-09-22 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| DE19949209A1 (de) * | 1999-10-13 | 2001-04-19 | Boehringer Ingelheim Pharma | In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| CZ301689B6 (cs) | 1999-11-05 | 2010-05-26 | Astrazeneca Ab | Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje |
| TR200201431T2 (tr) * | 1999-11-30 | 2002-09-23 | Pfizer Products Inc. | İmünosupresanlar olarak faydalı 2,4-diaminopirimidin bileşikleri |
| AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
| DE10054019A1 (de) * | 2000-11-01 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
-
2002
- 2002-08-16 DE DE10237423A patent/DE10237423A1/de not_active Withdrawn
-
2003
- 2003-08-11 EP EP10184940A patent/EP2281561A3/en not_active Withdrawn
- 2003-08-11 DK DK03792292T patent/DK1530466T3/da active
- 2003-08-11 EP EP03792292.9A patent/EP1530466B1/en not_active Expired - Lifetime
- 2003-08-11 SI SI200332413T patent/SI1530466T1/sl unknown
- 2003-08-11 JP JP2004530121A patent/JP2006514611A/ja active Pending
- 2003-08-11 WO PCT/EP2003/008890 patent/WO2004017948A2/en not_active Ceased
- 2003-08-11 CA CA2495350A patent/CA2495350C/en not_active Expired - Lifetime
- 2003-08-11 AU AU2003255413A patent/AU2003255413A1/en not_active Abandoned
- 2003-08-11 ES ES03792292T patent/ES2530392T3/es not_active Expired - Lifetime
- 2003-08-11 PT PT37922929T patent/PT1530466E/pt unknown
-
2015
- 2015-03-09 CY CY20151100238T patent/CY1116093T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1116093T1 (el) | 2017-02-08 |
| SI1530466T1 (sl) | 2015-03-31 |
| CA2495350C (en) | 2012-05-29 |
| PT1530466E (pt) | 2015-02-24 |
| JP2006514611A (ja) | 2006-05-11 |
| WO2004017948A2 (en) | 2004-03-04 |
| DE10237423A1 (de) | 2004-02-19 |
| WO2004017948A8 (en) | 2005-03-24 |
| AU2003255413A8 (en) | 2004-03-11 |
| EP1530466B1 (en) | 2014-12-10 |
| CA2495350A1 (en) | 2004-03-04 |
| WO2004017948A3 (en) | 2004-04-22 |
| EP2281561A2 (en) | 2011-02-09 |
| AU2003255413A1 (en) | 2004-03-11 |
| DK1530466T3 (da) | 2015-03-16 |
| EP2281561A3 (en) | 2012-05-09 |
| EP1530466A2 (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2530392T3 (es) | Uso del nintedanib para el tratamiento de la fibrosis pulmonar | |
| UA94390C2 (ru) | Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких | |
| SI1534390T1 (sl) | Z dimetilfenil dihidro metil okso H pirazol iliden hidrazino hidroksi bifenil karboksilna kislina bis monoetanolamin | |
| ZA200409814B (en) | 3-Z-(1-(4-(N-((4-methyl-piperazin-1-YL)-methylcarbnonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition. | |
| AP1718A (en) | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | |
| NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
| DK1268431T3 (da) | 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer | |
| NO20044137L (no) | Aminoindazolderivater, deres fremstilling og anvendelse samt mellomprodukter | |
| DOP2002000456A (es) | Inhibidores de la alquin-aril fosfodiesterasa-4'' | |
| DK1551511T5 (da) | Heterocykliske aromatiske forbindelser, der er anvendelige som væksthormonsekretagoger | |
| NO20051689D0 (no) | Substituerte piperaziner, (1,4) diaszepiner og 2,5-diazabicyklo(2.2.1) heptaner som histamin H1 og/eller H3 antagonister eller histamin H3 revers antagonister | |
| NO20031482L (no) | Nye tiadiazoler og oksadiazoler, og anvendelse derav som fosfodiesterase-7inhibitorer | |
| ITTO20030185A1 (it) | Stabilizzazione migliorata del disassamento per alesatori eccentrici. | |
| NO20013853D0 (no) | Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer | |
| AR038305A1 (es) | Composicion farmaceutica dispersable oralmente de perindopril | |
| NO20053598L (no) | Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister. | |
| AR045724A1 (es) | Composicion farmaceutica orodispersable de un compuesto antitrombotico | |
| ES2186375T3 (es) | Levosimendano para tratar el hipertension pulmonar. | |
| IS7705A (is) | 4-(3,5-Dísýanófenoxý) pýrasól afleiður til notkunar sem bakritunarstillar við meðhöndlun á m.a. eyðniveirunni | |
| IL171927A0 (en) | Use of tyrosine kinase inhibitor to treat diabetes | |
| BRPI0818065A8 (pt) | Quimioterapêutco derivado de indazol cristalino | |
| ITMI20021328A1 (it) | Nuove piperazine 1,4 - disostituite | |
| CY1105785T1 (el) | Μεθοδοι παρασκευης της 2-(7-χλωρο-1,8-ναφθυριδιν-2-υλ)-3-(5-μεθυλ-2-οξο-εξυλ)-1-ισοϊνδολινονης | |
| ITAT20020003A0 (it) | Serramento di oscuramento,in particolare di legno,e procedimento per la sua fabbricazione. | |
| AU2003259394A1 (en) | Preparation of 1-(4-(2-methoxy-phenyl)-piperazin-1-yl)-3-(2,6-dioxopiperidin-1-yl) propane hydrochloride |